Redefining high-risk prostate cancer based on distant metastases and mortality after high-dose radiotherapy with androgen deprivation therapy.

[1]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[2]  M. Cooperberg,et al.  Minimal impact of clinical stage on prostate cancer prognosis among contemporary patients with clinically localized disease. , 2010, The Journal of urology.

[3]  A. D'Amico,et al.  Androgen‐Deprivation Therapy in Prostate Cancer and Cardiovascular Risk: A Science Advisory From the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology , 2010, CA: a cancer journal for clinicians.

[4]  P. Scardino,et al.  Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Matthew R Cooperberg,et al.  Time trends and local variation in primary treatment of localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Weichselbaum,et al.  Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy. , 2009, International journal of radiation oncology, biology, physics.

[7]  M. Piérart,et al.  Duration of androgen suppression in the treatment of prostate cancer. , 2009, The New England journal of medicine.

[8]  A. D'Amico,et al.  Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. , 2009, JAMA.

[9]  A. Renshaw,et al.  Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials. , 2009, International journal of radiation oncology, biology, physics.

[10]  M. Roach,et al.  Predictive models in external beam radiotherapy for clinically localized prostate cancer , 2009, Cancer.

[11]  J. Lebesque,et al.  Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[12]  Yoshiya Yamada,et al.  Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. , 2008, International journal of radiation oncology, biology, physics.

[13]  Yoshiya Yamada,et al.  Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. , 2008, International journal of radiation oncology, biology, physics.

[14]  D. Grignon,et al.  Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Lei Dong,et al.  Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[16]  Sylvie Chabaud,et al.  Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Charles R. Thomas,et al.  An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. , 2007, International journal of radiation oncology, biology, physics.

[18]  M. Parmar,et al.  Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. , 2007, The Lancet. Oncology.

[19]  Anthony D'Amico,et al.  Prostate cancer. Clinical practice guidelines in oncology. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

[20]  A. D'Amico,et al.  Cancer‐specific mortality after radiation therapy with short‐course hormonal therapy or radical prostatectomy in men with localized, intermediate‐risk to high‐risk prostate cancer , 2006, Cancer.

[21]  Paul Schellhammer,et al.  Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.

[22]  Daniel W. Miller,et al.  Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. , 2005, JAMA.

[23]  James A Hanley,et al.  Prostate cancer and the Will Rogers phenomenon. , 2005, Journal of the National Cancer Institute.

[24]  A. Renshaw,et al.  Adult urologyUrological survey: urological oncology: prostate cancerPretreatment PSA Velocity and Risk of Death From Prostate Cancer Following External Beam Radiation Therapy , 2006 .

[25]  D. Grignon,et al.  Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. , 2005, International journal of radiation oncology, biology, physics.

[26]  A. Renshaw,et al.  Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Manola,et al.  6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. , 2004, JAMA.

[28]  Jacques Bernier,et al.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial , 2002, The Lancet.

[29]  M W Kattan,et al.  Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  A. Renshaw,et al.  Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer , 1998 .

[31]  A R Feinstein,et al.  The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. , 1985, The New England journal of medicine.